ERBB2 and breast carcinoma: Here, we confirmed new strategies in both HER2+ breast cancer and TNBC cell lines, not only by using the on-target effect of ERBB family protein inhibition but also by suppressing the compensatory PI3K-Akt-mTOR and MAPK pathways.